Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5D6ZM
|
|||
| Drug Name |
IK-175
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Urothelial carcinoma [ICD-11: 2C92.0] | Phase 1 | [1] | |
| Company |
Ikena Oncology
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aryl hydrocarbon receptor (AHR) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04200963) A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Ikena Oncology. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.